Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05532566

Quercus Ilex and Quercus Robur Allergen Extracts Standardisation

Quercus Ilex and Quercus Robur Allergen Extracts. Determination of the in Vivo Allergenic Potency in Histamine Equivalent Units (HEP).

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Inmunotek S.L. · Industry
Sex
All
Age
18 Years – 64 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).

Detailed description

The trial will consist of a single visit, in which the following procedures will be carried out: * Demographic data. * Clinical history. * Inclusion/exclusion criteria. * General examination. * Performance of prick-tests (3 concentrations of Quercus ilex allergenic extract, 3 concentrations of Quercus robur allergenic extract, positive control and negative control). * Obtaining a blood sample from the patient to create a pool of sera for the "in vitro" standardization of the allergenic extract. This pool of sera is necessary for the characterization of the Company's standard. Each serum sample will be stored in a tube that will be labeled with the subject number and frozen. These serum samples will remain in the freezer until the study is completed. When the study is completed, they will be transported to the laboratory, where all sera will be pooled. This "pool" of sera will be used to perform the complementary in vitro standardization tests. These include ELISA for measurement of inhibition against specific IgE, etc. These serum samples are not destroyed. They are pooled together to form a pool that will be used, as described in the previous paragraph, in all the in vitro tests necessary to standardize and characterize this extract and produce its corresponding HIRP (In-house reference preparation), as indicated by the Royal Spanish Pharmacopoeia and the European Pharmacopoeia. This pool of sera is not destroyed, it is used in the in vitro analyses necessary for the standardization of new batches of this allergenic extract. Once the pool has been formed, the tubes containing the original serum samples are destroyed. * Evaluation of adverse events.

Conditions

Interventions

TypeNameDescription
OTHERAllergenic extractIn each subject a drop of each of the 3 concentrations of both allergenic extracts will be applied in addition to the positive control (histamine) and the negative control. The application will be made in duplicate on the anterior face of the subject's arm. The distance between each application should be approximately 4 cm.

Timeline

Start date
2023-01-24
Primary completion
2025-11-30
Completion
2025-11-30
First posted
2022-09-08
Last updated
2025-05-01

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT05532566. Inclusion in this directory is not an endorsement.